Argent BioPharma Locks in 5-Year Global Royalty Deal for Its Skin Delivery Tech
Argent BioPharma secures long-term Aquiol licensing deal with global dermocosmetic platform
Argent BioPharma (ASX: RGT) has executed a long-term licensing and supply agreement with The Skin Health Institute Ltd (SHI), trading as MGC Derma, an Ireland-based dermatology and skin health company. The agreement grants SHI exclusive worldwide use of Aquiol™ for dermatology-focused cosmetic applications, marking a strategic expansion of the Company’s drug delivery technologies beyond pharmaceuticals into the dermatology and skin health sector.
When big ASX news breaks, our subscribers know first
What the agreement covers
Key commercial terms
The Argent BioPharma Aquiol licensing agreement establishes a five-year framework covering licensing, manufacturing, supply, royalties, and commercial collaboration in relation to dermatology-focused formulations and associated intellectual property.
Under its terms, SHI receives an “exclusive worldwide licence to utilise Aquiol™ and associated formulations for the manufacturing, marketing, and distribution of dermatology focused cosmetic products.” A long-term supply arrangement is also established, under which SHI will source Aquiol™ and related products from Argent BioPharma on arm’s length, commercial terms.
The royalty structure includes two components: a fixed monthly payment of €3,000 plus a 5% revenue-linked royalty on products incorporating Aquiol™ and the MGC Derma platform. The agreement also includes collaboration provisions relating to potential commercial opportunities within the United States dermatology and cosmetic markets.
| Term | Duration | Licence Scope | Fixed Royalty | Revenue Royalty |
|---|---|---|---|---|
| Licensing & Supply | 5 years | Exclusive worldwide — dermatology cosmetic applications | €3,000/month | 5% of product revenues |
Production and operational infrastructure
Production, formulation development, and future product expansion under the MGC Derma platform are expected to be conducted through Argent BioPharma’s Slovenian operational partners at NutraMind. This arrangement leverages the Company’s formulation capabilities, proprietary delivery system technologies, and integrated product development infrastructure.
Understanding Aquiol™ and the SNEEDS technology platform
Aquiol™ is a topical delivery platform based on the SNEEDS (Stable Nano Emulsion for Enhanced Drug/Delivery System) technology, jointly developed with Graft Bio. In practical terms, the system is designed to improve how active compounds penetrate the skin barrier, as larger particles typically struggle to cross this barrier effectively. SNEEDS addresses this through stable water-soluble formulation technology, improving bioavailability and topical delivery.
The platform is not new to Argent’s portfolio. It has previously been utilised in the Company’s pharmaceutical programmes, including CimetrA®, establishing it as a proven delivery system now being extended into a new commercial market. The formulations incorporated into the MGC Derma platform have also undergone prior clinical testing conducted by Argent BioPharma.
For investors, this is a meaningful distinction: the same proprietary intellectual property underpinning Argent’s pharmaceutical pipeline is now being applied to generate a commercial royalty revenue stream in the dermatology sector, without requiring the development of entirely new technology.
Roby Zomer, Chairman
“This agreement reflects Argent BioPharma’s strategy of expanding the application of its proprietary delivery and formulation technologies beyond pharmaceuticals into clinically positioned skin health and dermatology markets. MGC Derma and Aquiol™ provide a platform that combines clinically tested formulations, long-term supply economics, and differentiated delivery technologies within a growing global dermocosmetic sector.”
The next major ASX story will hit our subscribers first
Why this deal broadens Argent’s investment case
A credentialed partner in a growing sector
MGC Derma is a clinically positioned dermocosmetic platform focused on inflammation control, skin barrier repair, and the management of sensitive and problematic skin. The company’s advisory and commercial network provides a degree of credibility within premium and clinical skincare channels, including pharmacy, clinic, and professional skincare. That network includes:
- Dr Michele Verschoore, former L’Oréal dermatologist expert
- Sir Pali Hungin, former British Medical Association President
- Senior commercial executives from YSL and Burberry
The calibre of these advisers signals that MGC Derma is positioned as a science-led brand operating at the intersection of clinical dermatology and premium skincare, rather than a mass-market consumer play.
Diversified revenue alongside the core pipeline
The agreement aligns with Argent’s stated strategy of building diversified healthcare revenue streams alongside its neuro-immune focused pharmaceutical pipeline, which includes CannEpil® and CimetrA®. The Aquiol agreement adds a recurring royalty structure, comprising both the fixed monthly component and the revenue-linked royalty, to a company already described as revenue-generating.
The collaboration provisions relating to the United States dermatology and cosmetic markets represent a forward-looking commercial opportunity, the scale of which will depend on MGC Derma’s commercial execution in that geography. Taken together, the agreement extends the commercial reach of Argent’s proprietary IP while adding a structured, long-term revenue stream that operates independently of clinical trial outcomes.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.